| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910137119603321 |
|
|
Autore |
Wolfgang Christopher L. |
|
|
Titolo |
Cancer screening and genetics / / Christopher L. Wolfgang, MD, PhD |
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Philadelphia, Pennsylvania : , : Elsevier, , 2015 |
|
©2015 |
|
|
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (244 p.) |
|
|
|
|
|
|
Collana |
|
Surgical Clinics of North America, , 0039-6109 ; ; Volume 95, Number 5 |
|
|
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Cancer - Genetic aspects |
Cancer - Early detection |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references at the end of each chapters and index. |
|
|
|
|
|
|
|
|
Nota di contenuto |
|
Cover image; Title page; Table of Contents; Copyright; Contributors; Consulting Editor; Editor; Authors; Forthcoming Issues; Forthcoming Issues; Recent Issues; Foreword: Cancer Screening and Genomics; Preface; Background; Cancer Genetics and Implications for Clinical Management; Key points; Introduction; Understanding the cancer genome landscape and translating advances for therapeutic gain; Driver versus passenger mutations; Mutational signatures in cancer; Rationale of genotype-guided medicine; Managing tumor heterogeneity and resistance to targeted therapy |
Advancing molecular phenotype-guided therapy in pancreatic cancerIndividualized therapy initiatives; Inherited susceptibility of cancer in the era of next-generation sequencing; Exceptional responders; Summary; The Triple-Code Model for Pancreatic Cancer; Key points; Cross talk between genetics and epigenetics as a promising paradigm in pancreatology; Mechanistic basis of epigenetics: the nucleosome; Marking the genome by methylation; Epigenetic regulation by noncoding RNAs; Shaping gene expression through nuclear architecture |
Epigenetics opens a new era for pancreatic cancer markers and novel therapeutic modalitiesSummary; Principles of Cancer Screening; Key points; Introduction; Performance characteristics of screening tests; |
|
|
|
|
|
|
|
|
|
|
Measures of screening benefit; Common biases in assessing the benefits of screening; Harms of screening; Cost-effectiveness and targeted screening; Current recommended cancer screening tests in North America; Screening and Early Detection: Specific Diseases; Lung Cancer Screening; Key points; Introduction; Risks and harms of lung cancer screening; Practice of lung cancer screening; Summary |
Colorectal Cancer ScreeningKey points; Introduction: extent of the disease; Screening techniques and options; Clinical outcomes; Complications and concerns; Summary; Breast Cancer Screening; Key points; Introduction; Screening techniques and options; Personalized breast cancer screening; Complications and concerns; Summary; Screening for Viral Hepatitis and Hepatocellular Cancer; Key points; Screening for hepatitis B virus infection; Screening for hepatitis C virus infection; Diagnosing other viral hepatitides; Screening for hepatocellular carcinoma |
When to obtain a liver biopsy to diagnose hepatocellular carcinomaProstate Cancer Screening and the Associated Controversy; Key points; Introduction; Screening techniques and options; Clinical outcomes; Complications and concerns; Summary; Screening for Pancreatic Cancer; Key points; Introduction; How early does pancreatic cancer have to be detected for cure?; Target lesions; Who is at risk of developing pancreatic cancer? Who should be screened?; How should suspected lesions be managed?; Screening and Early Detection of Gastric Cancer; Key points |
Gastric cancer epidemiology: mortality, incidence between east and west |
|
|
|
|
|
| |